He Yukai, Munn David, Falo Louis D
Medical College of Georgia, Immunology/Immunotherapy Program, MCG Cancer Center, CN-4150, 1120 15th Street, Augusta, GA 30912, USA.
Expert Rev Vaccines. 2007 Dec;6(6):913-24. doi: 10.1586/14760584.6.6.913.
Encouraged by remarkable successes in preventing infectious diseases and by the well-established potential of the immune system for controlling tumor growth, active therapeutic immunization approaches hold great promise for treating malignant tumors. In recent years, engineered recombinant viral vectors have been carefully examined as genetic-immunization vehicles and have been demonstrated to induce potent T-cell-mediated immune responses that can control tumor growth. Very recent efforts suggest that lentivectors possess important advantages over other candidate recombinant viral vectors for genetic immunization. Here, we review the development of recombinant lentivectors and the characteristics of T-cell immune responses elicited by lentivector immunization, including the mechanism of T-cell priming with a focus on the role of skin dendritic cells and potential applications for tumor immunotherapy.
在预防传染病方面取得的显著成功以及免疫系统控制肿瘤生长的既定潜力的鼓舞下，主动治疗性免疫方法在治疗恶性肿瘤方面具有巨大潜力。近年来，工程重组病毒载体已作为基因免疫载体得到仔细研究，并已证明可诱导有效的T细胞介导的免疫反应，从而控制肿瘤生长。最近的研究表明，慢病毒载体在用于基因免疫的其他候选重组病毒载体方面具有重要优势。在这里，我们回顾了重组慢病毒载体的发展以及慢病毒载体免疫引发的T细胞免疫反应的特征，包括T细胞启动机制，重点是皮肤树突状细胞的作用以及肿瘤免疫治疗的潜在应用。
